Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 410 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence MOST POPULAR Bowel scope screening to stop in England January 14, 2021 Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to... June 16, 2021 FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer January 25, 2023 Taking on DNA repair to tackle cancer November 5, 2021 Load more HOT NEWS ΣΑΡΚΩΜΑ Finding Purpose During Cancer: A Survivor’s Story OncoArray Links Dozens of DNA Variants to Risk for Common Cancers Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with...
